Sarepta Therapeutics
SRPT
336 hedge funds and large institutions have $7.46B invested in Sarepta Therapeutics in 2018 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 126 increasing their positions, 111 reducing their positions, and 60 closing their positions.
52% more call options, than puts
Call options by funds: $283M | Put options by funds: $186M
14% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 111
5.32% more ownership
Funds ownership: 92.18% → 97.5% (+5.3%)
3% less funds holding
Funds holding: 345 → 336 (-9)
10% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 60
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
25% less capital invested
Capital invested by funds: $9.89B → $7.46B (-$2.43B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$179M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$149M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$131M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$84.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$60.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$59.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$35.5M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
-$33.3M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$28.1M |
| 5 |
Jennison Associates
New York
|
-$24.6M |
SRPT Hedge Fund Activity: Q4 2018 in Review
336 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2018, worth a combined $7.46B — down 25% from $9.89B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of SRPT and 54 opened new positions — a net loss of 6 holders — while 111 trimmed existing stakes and 126 added.
The largest buyer was Janus Henderson Group, adding an estimated $179M. The largest seller was Millennium Management, cutting an estimated $59.2M.
- 336 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2018, down from 345 in Q3 2018.
- Funds reported $7.46B of Sarepta Therapeutics stock for Q4 2018, down 25% quarter-over-quarter.
- 54 funds opened new Sarepta Therapeutics positions in Q4 2018 and 60 closed out, a net change of -6 holders.
- The largest Sarepta Therapeutics buyer in Q4 2018 was Janus Henderson Group, an estimated $179M added.
- The largest Sarepta Therapeutics seller in Q4 2018 was Millennium Management, an estimated $59.2M sold.
Based on aggregated 13F filings for Q4 2018.